$FBRX
Forte Biosciences, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022017378 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.044M $1.986M $1.821M
YoY Change 0.05% -10.7% 28.24%
% of Gross Profit
Research & Development $1.379M $1.034M $693.0K
YoY Change -75.62% -70.65% -79.14%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
% of Gross Profit
Operating Expenses $3.423M $3.020M $2.514M
YoY Change -55.54% -47.45% -46.97%
Operating Profit -$3.423M -$3.020M -$2.514M
YoY Change -55.54% -47.45% -46.97%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $23.00K -$15.00K -$53.00K
YoY Change -144.23% -76.92% -15.87%
Pretax Income -$3.400M -$3.035M -$2.567M
YoY Change -56.13% -47.78% -46.52%
Income Tax
% Of Pretax Income
Net Earnings -$3.400M -$3.035M -$2.567M
YoY Change -56.13% -47.78% -46.57%
Net Earnings / Revenue
Basic Earnings Per Share -$0.18 -$0.21 -$0.17
Diluted Earnings Per Share -$0.18 -$0.21 -$173.9K
COMMON SHARES
Basic Shares Outstanding 20.34M 14.76M 14.76M
Diluted Shares Outstanding 18.93M 14.76M 14.76M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $44.05M $38.55M $40.04M
YoY Change -3.54% -24.11% -26.94%
Cash & Equivalents $44.00M $38.50M $40.00M
Short-Term Investments
Other Short-Term Assets $546.0K $298.0K $376.0K
YoY Change -38.72% -72.56% -65.82%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $44.59M $38.85M $40.41M
YoY Change -4.21% -25.12% -27.71%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $534.0K $874.0K $893.0K
YoY Change -35.97% -6.62% -19.77%
Total Long-Term Assets $534.0K $874.0K $893.0K
YoY Change -35.97% -13.12% -25.58%
TOTAL ASSETS
Total Short-Term Assets $44.59M $38.85M $40.41M
Total Long-Term Assets $534.0K $874.0K $893.0K
Total Assets $45.13M $39.72M $41.30M
YoY Change -4.77% -24.9% -27.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.191M $698.0K $576.0K
YoY Change -48.88% -29.14% -52.0%
Accrued Expenses $1.102M $815.0K $680.0K
YoY Change -21.84% -59.11% -41.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.293M $1.513M $1.256M
YoY Change -38.69% -49.19% -47.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.293M $1.513M $1.256M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.293M $1.513M $1.256M
YoY Change -38.69% -49.19% -47.67%
SHAREHOLDERS EQUITY
Retained Earnings -$82.20M -$78.80M -$75.70M
YoY Change 17.77% 26.89% 34.46%
Common Stock $125.0M $117.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $42.84M $38.21M $40.05M
YoY Change
Total Liabilities & Shareholders Equity $45.13M $39.72M $41.30M
YoY Change -4.77% -24.9% -27.66%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$3.400M -$3.035M -$2.567M
YoY Change -56.13% -47.78% -46.57%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Cash From Operating Activities -$1.940M -$1.377M -$2.000M
YoY Change -62.16% -65.03% -50.37%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.440M -110.0K -34.00K
YoY Change -248100.0% 243.75% -225.93%
NET CHANGE
Cash From Operating Activities -1.940M -1.377M -2.000M
Cash From Investing Activities
Cash From Financing Activities 7.440M -110.0K -34.00K
Net Change In Cash 5.500M -1.487M -2.009M
YoY Change -207.21% -62.54% -49.81%
FREE CASH FLOW
Cash From Operating Activities -$1.940M -$1.377M -$2.000M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001419041
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38052
dei Entity Registrant Name
EntityRegistrantName
FORTE BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1243872
dei Entity Address Address Line1
EntityAddressAddressLine1
3060 Pegasus Park Drive, Building 6
dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20340265
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75247
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38548000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42044000
dei City Area Code
CityAreaCode
310
dei Local Phone Number
LocalPhoneNumber
618-6994
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
298000
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
FBRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
476000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
38846000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
42520000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
874000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
786000
CY2022Q2 us-gaap Assets
Assets
39720000
CY2021Q4 us-gaap Assets
Assets
43306000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
698000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
946000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
815000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
812000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1513000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1758000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14761261
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14761261
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14754447
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14754447
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
15000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
116959000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
114698000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78767000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73165000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
38207000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41548000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39720000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43306000
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1034000
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3523000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1727000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6845000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1986000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2224000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3807000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3643000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3020000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
5747000
us-gaap Operating Expenses
OperatingExpenses
5534000
us-gaap Operating Expenses
OperatingExpenses
10488000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3020000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5747000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5534000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10488000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-65000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-68000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-128000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3035000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5812000
us-gaap Net Income Loss
NetIncomeLoss
-5602000
us-gaap Net Income Loss
NetIncomeLoss
-10616000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14761261
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14761261
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13603181
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13603181
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14760538
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14760538
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13429018
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13429018
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
58980000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
495000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4804000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
54698000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1008000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5812000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
49909000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41548000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
11000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1055000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2567000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
40048000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1194000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3035000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
38207000
us-gaap Net Income Loss
NetIncomeLoss
-5602000
us-gaap Net Income Loss
NetIncomeLoss
-10616000
us-gaap Depreciation
Depreciation
27000
us-gaap Share Based Compensation
ShareBasedCompensation
2249000
us-gaap Share Based Compensation
ShareBasedCompensation
1503000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-275000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-399000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-277000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-255000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
974000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3352000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7968000
fbrx Proceeds From Exercise Of Stock Options And Employee Stock Purchase Plan
ProceedsFromExerciseOfStockOptionsAndEmployeeStockPurchasePlan
12000
fbrx Proceeds From Exercise Of Stock Options And Employee Stock Purchase Plan
ProceedsFromExerciseOfStockOptionsAndEmployeeStockPurchasePlan
42000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
156000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
44000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-144000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3496000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7970000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42044000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58765000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38548000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50795000
fbrx Unpaid Deferred Transaction Costs
UnpaidDeferredTransactionCosts
29000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78800000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3400000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38500000
CY2022Q2 fbrx Transfers Between Fair Value Hierarchy Levels
TransfersBetweenFairValueHierarchyLevels
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. Significant management estimates that affect the reported amounts of assets, liabilities and expenses include stock-based compensation expense, accruals and deferred tax assets. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2602021
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2428454
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
204000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
387000
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
94000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
89000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
298000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
476000
CY2022Q2 fbrx Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
570000
CY2021Q4 fbrx Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
667000
CY2022Q2 fbrx Prepaid Offering Costs
PrepaidOfferingCosts
291000
CY2021Q4 fbrx Prepaid Offering Costs
PrepaidOfferingCosts
106000
CY2022Q2 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
13000
CY2021Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
13000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
874000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
786000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
102000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
75000
CY2022Q2 fbrx Accrued Compensation
AccruedCompensation
454000
CY2021Q4 fbrx Accrued Compensation
AccruedCompensation
681000
CY2022Q2 fbrx Accrued Manufacturing And Clinical Expenses
AccruedManufacturingAndClinicalExpenses
208000
CY2021Q4 fbrx Accrued Manufacturing And Clinical Expenses
AccruedManufacturingAndClinicalExpenses
40000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
51000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
16000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
815000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
812000
CY2022Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q2 us-gaap Royalty Expense
RoyaltyExpense
0
CY2021Q2 us-gaap Royalty Expense
RoyaltyExpense
25000
us-gaap Royalty Expense
RoyaltyExpense
25000
us-gaap Royalty Expense
RoyaltyExpense
50000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
3000
us-gaap Operating Lease Expense
OperatingLeaseExpense
6000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
6000
fbrx Rent Credit Due To Refund For Operating Expense Adjustments
RentCreditDueToRefundForOperatingExpenseAdjustments
9000
CY2022Q2 us-gaap Contractual Obligation
ContractualObligation
199000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.82
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.92
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.29
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y7M2D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
218000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
361666
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
22.41
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M17D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
16000
fbrx Share Based Compensation Arrangement By Share Based Payment Award Options Fair Value Of Stock Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueOfStockPrice
1.30
CY2022Q2 fbrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
1.28
CY2021Q2 fbrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
38.14
fbrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
1.49
fbrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
37.89
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0306
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0103
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0225
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0096
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M10D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M2D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M17D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M20D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7145
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6970
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6857
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6980
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1281396
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.18
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M8D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1149166
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.49
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1098
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
90728
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
31.80
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2338736
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.46
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M2D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
218000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2338736
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.46
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1194000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1008000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2249000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1503000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
8000000.0
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M21D

Files In Submission

Name View Source Status
0000950170-22-017378-index-headers.html Edgar Link pending
0000950170-22-017378-index.html Edgar Link pending
0000950170-22-017378.txt Edgar Link pending
0000950170-22-017378-xbrl.zip Edgar Link pending
fbrx-20220630.htm Edgar Link pending
fbrx-20220630.xsd Edgar Link pending
fbrx-ex10_1.htm Edgar Link pending
fbrx-ex10_2.htm Edgar Link pending
fbrx-ex31_1.htm Edgar Link pending
fbrx-ex31_2.htm Edgar Link pending
fbrx-ex32_1.htm Edgar Link pending
fbrx-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img89987042_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
fbrx-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
fbrx-20220630_lab.xml Edgar Link unprocessable
fbrx-20220630_pre.xml Edgar Link unprocessable
fbrx-20220630_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
fbrx-20220630_cal.xml Edgar Link unprocessable